When it comes to the diabetes tech market, the Insulet (Nasdaq:PODD) Omnipod 5 automated insulin delivery system is nothing new. Omnipod 5 first received FDA clearance for individuals aged six years old and up with type 1 diabetes in January 2022. … [Read More...] about Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
Main Content
Sponsored Content
Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Manufacturing automation is crucial to achieving the precision, quality, and volume required in the medical device industry. Advanced robotics, AI, modular designs, and wireless technology offer the … [Read More...] about Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Featured Posts
Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
When it comes to the diabetes tech market, the Insulet (Nasdaq:PODD) Omnipod 5 automated insulin delivery system is nothing new. Omnipod 5 first received FDA clearance for individuals aged six years old and up with type 1 diabetes in January 2022. … [Read More...] about Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
Abbott Diabetes head talks Medtronic partnership, exciting times ahead
For many, a partnership between Abbott (NYSE:ABT) and Medtronic (NYSE:MDT), two medtech giants and frequent competitors, would have seemed unlikely. The two companies battle for market share in a variety of spaces, including cardiac implants, … [Read More...] about Abbott Diabetes head talks Medtronic partnership, exciting times ahead
PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
While many existing systems already pair continuous glucose monitors (CGMs) and insulin pumps, PharmaSens and SiBionics may have something different to offer. Current automated insulin delivery platforms — like those offered by Insulet, Tandem … [Read More...] about PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy
A new study has demonstrated proof of concept for a Biolinq continuous sensor in preventing muscle loss during GLP-1 therapy. Investigators presented findings as a late-breaking poster at the American Diabetes Association's 85th Scientific … [Read More...] about Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy
Next-gen Medtronic insulin pump reportedly set for FDA submission, patch pump on the way
BTIG analysts said today that MiniMed, the Medtronic (NYSE:MDT) diabetes business, has some significant pipeline updates. Marie Thibault, Sam Eiber and Alexandra Pang shared notes from their meeting with Que Dallara, soon-to-be CEO of the to-be … [Read More...] about Next-gen Medtronic insulin pump reportedly set for FDA submission, patch pump on the way
Analysts expect Beta Bionics patch pump launch by 2027
BTIG analysts said today that Beta Bionics (Nasdaq:BBNX) expects to launch a new insulin patch pump system in the U.S. by the end of 2027. Marie Thibault, Sam Eiber and Alexandra Pang said the company revealed the new Mint system in a live … [Read More...] about Analysts expect Beta Bionics patch pump launch by 2027
A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
Glucotrack (Nasdaq:GCTK) believes it can tap into a diabetes market that includes millions of people who aren't being served completely. That's according to the company's Chief Scientific Officer, Mark Tapsak, who gave a presentation on the … [Read More...] about A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
Dexcom continues advances in AI for CGM, type 2 diabetes awareness
As one of the leaders in continuous glucose monitoring (CGM) technology, Dexcom (Nadsaq:DXCM) continues to expand its capabilities. The company has hit a number of milestones recently, including updated CGMs, new AI capabilities, expanded … [Read More...] about Dexcom continues advances in AI for CGM, type 2 diabetes awareness
Tandem continues to deliver more options, benefits for those with diabetes
It's been a busy couple of years for Tandem Diabetes Care (Nasdaq:TNDM) and it doesn't look like slowing down any time soon. The San Diego-based automated insulin delivery system developer offers two differentiated pump platforms — the … [Read More...] about Tandem continues to deliver more options, benefits for those with diabetes
Breaking: Sequel to launch twiist automated insulin delivery system next month
Sequel Med Tech announced at the American Diabetes Association's 85th Scientific Sessions in Chicago that it plans to launch its twiist system in July. Dr. Joanna Mitri, the company's chief medical officer, shared the update in a Product Theater … [Read More...] about Breaking: Sequel to launch twiist automated insulin delivery system next month
In case you missed it
- Dexcom shares U.S. report on CGM benefits for type 2 diabetes
- Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
- Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
- Abbott could pave new roads in diabetes management with dual sensor on the horizon
- Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
- Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
- PharmaSens, SiBionics collab on all-in-one insulin patch pump
- Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor
- CeQur hits insulin patch milestone, highlights commercial expansion
- Zyno recalls certain infusion pumps due to software issue
- Ypsomed, CamDiab continue global insulin pump iPhone software rollout
- Dexcom has a Class I CGM receiver recall
- Medtronic to invest $50M in India Diabetes center
- Flat Medical partners with Mercury Medical on smart syringe distribution
- Glucotrack to effect a reverse stock split
Clinical Trials
Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
When it comes to the diabetes tech market, the Insulet (Nasdaq:PODD) Omnipod 5 automated insulin delivery system is nothing new. Omnipod 5 first received FDA clearance for individuals aged six years old and up with type 1 diabetes in January 2022. At that point, it became the world’s first available tubeless, wearable, automated insulin delivery […]
LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
LifePlus today announced the clinical validation of its LifeLeaf non-invasive and cuffless wearable for continuous glucose and blood pressure tracking. The device delivers real-time insights without needles, invasive sensors or cuffs. Global, multi-center trials conducted across the Mayo Clinic, AMCR Clinic – San Diego Cleveland Clinic – Abu Dhabi, and Hospital Sebarang Jaya – Penang, […]
Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy
A new study has demonstrated proof of concept for a Biolinq continuous sensor in preventing muscle loss during GLP-1 therapy. Investigators presented findings as a late-breaking poster at the American Diabetes Association’s 85th Scientific Sessions in Chicago. Using a DNA-based bioreceptor (aptamer), Biolinq designed its sensor to detect phenylalanine, an essential amino acid. Released from […]
Vaxess study highlights GLP-1 delivery with microarray patch
Vaxess Technologies today shared new preclinical data highlighting the capability of its drug delivery patch to deliver semaglutide. Semaglutide, a GLP-1 receptor agonist, is currently a treatment option for both diabetes and obesity management. Woburn, Massachusetts-based develops a microarray patch (MAP) designed to deliver drugs. It features a soluble microarray with tips that gradually dissolve […]
Lilly to submit once-weekly insulin for regulatory review this year following strong clinical results
Eli Lilly (NYSE:LLY) today announced positive safety and efficacy data for its investigational once-weekly insulin efsitora alfa (efsitora). The QWINT-1, QWINT-3 and QWINT-4 Phase 3 clinical trials evaluated efsitora in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily basal insulin and mealtime insulin, […]
